ERBB2 and invasive ductal breast carcinoma: The majority of patients had invasive histology in both the high-risk HER2+ group (94.3% invasive ductal carcinoma [IDC] and 3.3% invasive lobular carcinoma [ILC]) and the non-high-risk group (92.3% IDC and 3.7% ILC).